Your browser doesn't support javascript.
Characteristics and Factors Associated With Mortality in Patients With Coronavirus Disease 2019 and Pneumothorax.
Malik, Salik; Kaushik, Chandani; Heidelman, Eric; Polychronopoulou, Efstathia; Kuo, Yong-Fang; Sharma, Gulshan; Nishi, Shawn P E.
  • Malik S; Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas.
  • Kaushik C; Division of Pulmonary, Critical Care & Sleep Medicine, University of Texas Medical Branch, Galveston, Texas.
  • Heidelman E; Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas.
  • Polychronopoulou E; Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas.
  • Kuo YF; Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas.
  • Sharma G; Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas.
  • Nishi SPE; Sealy Center on Aging, University of Texas Medical Branch, Galveston, Texas.
Mayo Clin Proc Innov Qual Outcomes ; 6(3): 257-268, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1864618
ABSTRACT

Objective:

To describe the incidence, clinical characteristics, and factors associated with mortality in patients hospitalized for coronavirus disease 2019 (COVID-19) in whom pneumothorax developed. Patients and

Methods:

This study was a retrospective analysis conducted using a large administrative database of adult patients hospitalized for COVID-19 in the United States from February 1, 2020, to June 10, 2021. We characterized the clinical features of patients in whom pneumothorax developed and the factors associated with mortality and stratified pneumothorax by the timing of the initiation of invasive mechanical ventilation (IMV) and by the time of hospital admission (early versus late).

Results:

A total of 811,065 adult patients had a positive test result for severe acute respiratory syndrome coronavirus 2, of whom 103,858 (12.8%) were hospitalized. Pneumothorax occurred in 1915 patients (0.24% overall and 1.84% among hospitalized patients). Over time, the use of steroids and remdesivir increased, whereas the use of IMV, pneumothorax rates, and mortality decreased. The clinical characteristics associated with pneumothorax were male sex; the receipt of IMV; and treatment with steroids, remdesivir, or convalescent plasma. Most patients with pneumothorax received IMV, but pneumothorax developed before the initiation of IMV and/or early during hospitalization in majority. Multivariable analysis revealed that pneumothorax increased the risk of death (adjusted hazard ratio [aHR], 1.15; 95% CI, 1.06-1.24). In patients who did not receive IMV, pneumothorax led to nearly twice the mortality (aHR, 1.99; 95% CI, 1.56-2.54). Increased mortality was also noted when pneumothorax occurred before IMV (aHR, 1.37; 95% CI, 1.11-1.69) and within 7 days of hospital admission (aHR, 1.60; 95% CI, 1.29-1.98).

Conclusion:

The overall incidence of pneumothorax in patients hospitalized for COVID-19 was low. Pneumothorax is an independent risk factor for death.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Journal: Mayo Clin Proc Innov Qual Outcomes Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Journal: Mayo Clin Proc Innov Qual Outcomes Year: 2022 Document Type: Article